Artwork

Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

🌐 ACHIEVE-1 Decoded: Efficacy & Safety of Orforglipron in Type 2 Diabetes

3:43
 
Share
 

Manage episode 491318606 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

🚨 New Breakthrough in Type 2 Diabetes Care! 💊🧬

The ACHIEVE-1 trial shows that Orforglipron, a once-daily oral, nonpeptide GLP-1 receptor agonist, delivers significant reductions in HbA1c and body weight—without injections and with minimal restrictions! 🌍📉

👨‍⚕️ 559 patients across 5 countries

⏱️ 40 weeks, 3 dosing arms (3, 12, 36 mg)

📊 HbA1c ↓ by up to 1.48%, weight ↓ up to 7.6%

✅ No severe hypoglycemia

📌 Mild GI side effects during dose titration

This is a potential gamechanger for early T2DM care—simple, effective, and patient-friendly. 🚀

#Type2Diabetes #GLP1 #Orforglipron #Endocrinology #ClinicalTrials #PrecisionMedicine #Innovation #NEJM #ACHIEVE1 #OralTherapeutics 💥

  continue reading

537 episodes

Artwork
iconShare
 
Manage episode 491318606 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

🚨 New Breakthrough in Type 2 Diabetes Care! 💊🧬

The ACHIEVE-1 trial shows that Orforglipron, a once-daily oral, nonpeptide GLP-1 receptor agonist, delivers significant reductions in HbA1c and body weight—without injections and with minimal restrictions! 🌍📉

👨‍⚕️ 559 patients across 5 countries

⏱️ 40 weeks, 3 dosing arms (3, 12, 36 mg)

📊 HbA1c ↓ by up to 1.48%, weight ↓ up to 7.6%

✅ No severe hypoglycemia

📌 Mild GI side effects during dose titration

This is a potential gamechanger for early T2DM care—simple, effective, and patient-friendly. 🚀

#Type2Diabetes #GLP1 #Orforglipron #Endocrinology #ClinicalTrials #PrecisionMedicine #Innovation #NEJM #ACHIEVE1 #OralTherapeutics 💥

  continue reading

537 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play